Opendata, web and dolomites

PHARMS SIGNED

Bacteriophage inhibition of antibiotic-resistant pathogenic microbes and founding for novel therapeutic strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PHARMS project word cloud

Explore the words cloud of the PHARMS project. It provides you a very rough idea of what is the project "PHARMS" about.

pylori    resistant    inhibitors    sequence    screen    pharms    validation    genes    fight    acinetobacter    mediated    strategies    ranging    isolates    elucidating    array    functions    delivered    vectors    vivo    bacteriophages    worldwide    700    pathogens    scientific    emergence    universal    action    enzymes    vitro    phage    alien    complement    utilizes    positioned    throughput    revolutionary    confirmation    wp2    mechanisms    multiple    wp1    molecular    biology    battery    inhibition    diseases    plan    driving    obstacles    clinical    encoded    therapies    time    levels    life    lines    independent    interdisciplinary    rational    phages    employ    killed    wp3    ways    antibiotics    mimic    building    tools    group    resistance    limited    transcription    culture    host    infectious    amr    discovered    transport    bactericidal    elucidate    people    nucleotide    threatening    discoveries    treating    multifaceted    antimicrobial    grand    deploy    translation    discover    bacteria    modes    therapeutic    influenzae    unknown    haemophilus    isolate    framework    engineer    therapy    peptides    viruses    synthetic    bacterial    helicobacter    baumannii    natural   

Project "PHARMS" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH 

Organization address
address: INGOLSTADTER LANDSTRASSE 1
city: NEUHERBERG
postcode: 85764
website: www.helmholtz-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙650 €
 EC max contribution 1˙499˙650 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) coordinator 1˙499˙650.00

Map

 Project objective

Emergence of antimicrobial resistance (AMR) is a grand scientific challenge of our time that has killed more than 700,000 people worldwide. Phage therapy, a promising complement to antibiotics, utilizes viruses of bacteria (bacteriophages) or phage-derived inhibitors as natural ways to fight AMR. The main obstacles in the clinical application of phage-based AMR therapy are the limited number of phage isolates and the unknown molecular mechanisms of phage-delivered bactericidal action. Building on the recent advances of my group in high-throughput, culture-independent but host-targeted methodologies, PHARMS aims to deploy a revolutionary approach: to screen for all possible phages of a resistant bacterial isolate, characterize multiple lines of their bactericidal functions, and use this information for the design of a whole battery of phage-based therapies that employ multifaceted modes of action.

Using an interdisciplinary research plan, PHARMS will discover phage-specific bactericidal action modes at all possible levels ranging from nucleotide sequence and transcription to translation, in order to elucidate the molecular mechanisms driving phage-mediated inhibition of AMR Acinetobacter baumannii, Helicobacter pylori, & Haemophilus influenzae (WP1). These discoveries, together with novel synthetic biology tools, will enable us to engineer an array of phage vectors that mimic phage-deployed bactericidal modes discovered under WP1, including transport of alien genes to deliver bactericidal effects (WP2). PHARMS will provide molecular confirmation and in vitro & in vivo validation of the functions of phage-encoded bactericidal peptides and enzymes (WP3). By elucidating universal and specific mechanisms of phage-delivered inhibition of AMR pathogens, PHARMS is positioned to provide the rational framework for the design of novel therapeutic strategies aimed at treating common and life-threatening infectious diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHARMS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHARMS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More